[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571220":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":71,"collaborators":24,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":24,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":24,"maxAge":24,"enrollmentInfo":83,"targetDuration":24,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":24,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Xijing Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Conbercept 0.25 mg\u002F0.025mL","ACTIVE_COMPARATOR","intravitreal injection in both eyes on Day 0, with up to 1 re-treatment allowed for each eye if required",[13],"Drug: Conbercept",{"label":15,"type":16,"description":11,"interventionNames":17},"Conbercept 0.15 mg\u002F0.015mL","EXPERIMENTAL",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Conbercept","Administered as an intravitreal injection",[15,9],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Wang","CONTACT","02984771794","wangys003@126.com",[32,51,58],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Medical University","RECRUITING","Xi'an","Shaanxi","710032","China","CN",{"type":41,"coordinates":42},"Point",[43,44],108.92861,34.25833,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":24,"email":50},"He","02984771273","openji7127@hotmail.com",{"facility":52,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Department of Ophthalmology, Xijing Hospital, Air Force Military Medical University",{"type":41,"coordinates":54},[43,44],{"lat":44,"lon":43},[57],{"name":27,"role":28,"phone":49,"phoneExt":24,"email":30},{"facility":59,"status":34,"city":60,"state":36,"zip":61,"country":38,"countryCode":39,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Department of Ophthalmology, Xianyang Rainbow Hospital","Xianyang","712000",{"type":41,"coordinates":63},[64,65],108.70261,34.33778,{"lat":65,"lon":64},[68],{"name":69,"role":28,"phone":49,"phoneExt":24,"email":70},"Xue","1915992512@qq.com",{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Wang Yusheng","Professor","100571220","efficacy-and-safety-of-low-dose-conbercept-for-retinopathy-of-prematurity-therapy-100571220",false,"NCT06717412","Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy","Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy: A Multicenter, Prospective, Randomized, Double-blind, Non-inferiority Clinical Trial","Inclusion Criteria:\n\n* Preterm infants with less than or equal to 2000 grams of birth weight or less than or equal to 32 weeks of gestational age\n* Bilateral type 1 ROP with one of the following retinal findings in each eye\n* Zone I, stage 1+, 2+, 3+\u002F- disease, or\n* Zone II, stage 2+, 3+, disease, or\n* A-ROP\n\nExclusion Criteria:\n\n* Preterm infants with stage 4 or 5 ROP in one or both eyes\n* Have received any previous surgical or nonsurgical treatment for ROP, including laser photocoagulation, anti-VEGF therapy, vitrectomy\n* Have been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)\n* Have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer\n* Have active ocular infection within 5 days before or on the day of first investigational treatment\n* Have a history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes\n* Have any contraindication for intravitreal injection clearly stated in the instructions\n* Have any ocular structural abnormality that may affect efficacy assessments\n* Have a history of any other congenital or systemic conditions that are assessed by the investigator to have a significant risk of severe impact on visual function\n* Have any other medical conditions or clinically significant comorbidities or personal circumstances that are assessed by the investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments","ALL",{"count":84,"type":85},146,"ESTIMATED","INTERVENTIONAL",[88],"NA","Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)",[91],"Retinopathy of Prematurity (ROP)","2025-04-01",{"date":94,"type":95},"2025-04-04","ACTUAL",{"date":97,"type":95},"2024-11-29",{"date":99,"type":85},"2026-12-31",{"name":73,"class":6},3]